TNF and inflammatory bowel disease: The cellular and serum levels of eNAMPT are increased in patients with IBD who are unresponsive to anti-TNFα treatment (adalimumab or infliximab); and eNAMPT levels decrease in responsive patients to values comparable with those of healthy controls [15,16].